Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery · 01.06.2010 · 5 (2) · 109-117
DOI: 10.2174/157488910791213130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Recent Patents on CNS Drug Discovery, erschienen am 01.06.2010. Verfasst von Christian Holscher. Beteiligte Einrichtung: School of Biomedical Sciences, Ulster University, Cromore road, Coleraine BT52 1SA, UK. c.holscher@ulster.ac.uk. Die Arbeit wurde bisher 85-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Analogues of the incretins Glucagon-like peptide 1 (GLP-1) and Glucose-dependent insulinotropic peptide (GIP) have been developed to treat type 2 diabetes mellitus. They are protease resistant and have a longer biological half life than the native peptides. Some of these novel analogues can cross the blood-brain barrier, have neuroprotective effects, activate neuronal stem cells in the brain, and can improve cognition. The receptors for GIP and GLP-1 are expressed in neurons, and both GIP and GLP-1 are expressed and released as transmitters by neurons. GIP analogues such as DAla(2)GIP and GLP-1 analogues such as liraglutide enhance synaptic plasticity in the brain and also reverse the betaamyloid induced impairment of synaptic plasticity. In mouse models of Alzheimer's disease, GLP-1 analogues Val(8)GLP-1 and liraglutide prevent memory impairment and the block of synaptic plasticity in the brain. Since two GLP- 1 analogues exendin-4 (Exenatide, Byetta) and liraglutide (Victoza) are already on the market as treatments for Type 2 diabetes, and others are in late stage clinical trials, these drugs show promise as treatments for neurodegenerative diseases such as Alzheimer's disease. Currently, there are three patents covering native GLP-1 and different GLP-1 analogues and one patent for the use of GIP and different GIP analogues for the treatment of neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Ulster University, Cromore road, Coleraine BT52 1SA, UK. c.holscher@ulster.ac.uk
Zitieren
APA
Holscher, C. (2010). Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease. Recent Patents on CNS Drug Discovery, 5(2), 109-117. https://doi.org/10.2174/157488910791213130
Vancouver
Holscher C. Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease. Recent Patents on CNS Drug Discovery. 2010;5(2):109-117. doi:10.2174/157488910791213130
BibTeX
@article{Holscher2010,
author = {Holscher, Christian},
title = {Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease},
journal = {Recent Patents on CNS Drug Discovery},
year = {2010},
volume = {5},
number = {2},
pages = {109--117},
doi = {10.2174/157488910791213130}
}
EUVIMED